Fecal Microbiota Transplant Therapy May Change Paradigm of C. Difficile Treatment
Spherix Global Insights estimates that SER-109 (Seres Therapeutics; Aimmune) will be able to challenge fecal microbiota, live-jslm in C. difficile treatment.
Source: pharmacytimes.com